Market Cap 11.82M
Revenue (ttm) 0.00
Net Income (ttm) -16.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,092,100
Avg Vol 4,412,956
Day's Range N/A - N/A
Shares Out 49.06M
Stochastic %K 18%
Beta 3.17
Analysts Strong Sell
Price Target $3.25

Company Profile

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Industry: Biotechnology
Sector: Healthcare
Phone: 203 221 7381
Fax: 203 557 3023
Address:
1 Enterprise Drive, Suite 430, Shelton, United States
Wolfsschanze
Wolfsschanze Oct. 25 at 2:23 PM
$INTS ***Klinische Studien und Daten: Klinische Studien sind entscheidend, um zu zeigen, dass ihre Therapien tatsächlich wirksam sind und weniger Nebenwirkungen haben als traditionelle Chemotherapien oder andere Immuntherapien. Erfolgreiche Ergebnisse aus den laufenden Phase-1- und Phase-2-Studien könnten die Marktposition des Unternehmens erheblich stärken. Partnerschaften und Finanzierungen: Partnerschaften mit größeren Pharmaunternehmen oder zusätzliche Finanzierungsrunden sind wichtig, um die klinischen Tests weiterzuführen. Falls das Unternehmen in der Lage ist, Kooperationen einzugehen oder neues Kapital zu beschaffen, kann dies seine Chancen auf Erfolg weiter steigern.
0 · Reply
Pettechfl
Pettechfl Oct. 25 at 6:54 AM
$INTS https://www.zacks.com/stock/research/INTS/price-target-stock-forecast https://allianceg.com/researchteammember/james-molloy/ https://www.benchmarkcompany.com/leaders/robert-wasserman/ https://www.linkedin.com/in/kumarraja
0 · Reply
peterpancake
peterpancake Oct. 24 at 10:29 PM
$INTS Based on the cash raised through July 2025, we now project to have sufficient cash to fund our current operating plan into the second half of 2026."
0 · Reply
peterpancake
peterpancake Oct. 24 at 8:00 PM
$INTS yeah but there is no news. They literally have said nothing since September 9th. Almost 2 months with nothing other than RS stuff. This is bull crap
0 · Reply
lamMBD
lamMBD Oct. 24 at 7:34 PM
$INTS Part 3 In saying all of that, shares are NOW IN EXTREMELY TIGHT HANDS!!! Catalysts will ignite the spark here and this level will be a thing of the past!! The woulda coulda shoulda conversation!! I have been an investor for over forty plus years.Proud to still be in the game! However, in the 80s and 90s, it wasn't a game. People were more honest looking to help one another out sticking together and beating the markets and it's evil corruption, fighting together so that we all could prosper! Oh how i truly miss those days!! Part 4
3 · Reply
lamMBD
lamMBD Oct. 24 at 7:19 PM
$INTS PART 1 This post is for all longs this is my second time lost first LONG message unfortunately!! After extensive dd, over the last forty eight hours, I have come to the conclusion that the float here in INTS is the tightest that it has ever been!! The numbers that I came up with are 10-15M! If you are paying close attention to how INTS you is trading, it moves very quickly on up buys! What we are waiting for now longs are catalysts to start flowing! When these catalysts start coming out, and they will VERY SOON, there will be no stopping INTS as it heads its way to nasdaq compliance and above!! Part 2 coming up
1 · Reply
peterpancake
peterpancake Oct. 24 at 6:11 PM
CT-based biotech moves ahead with reverse-split plan $INTS https://hartfordbusiness.com/article/ct-based-biotech-moves-ahead-with-reverse-split-plan/
0 · Reply
peterpancake
peterpancake Oct. 24 at 6:09 PM
Connecticut Biotech Firm Intensity Therapeutics Navigates Critical Reverse Stock Split for Long Term Strategy $INTS https://markets.financialcontent.com/wral/article/marketminute-2025-10-24-connecticut-biotech-firm-intensity-therapeutics-navigates-critical-reverse-stock-split
0 · Reply
Viks25
Viks25 Oct. 24 at 1:52 PM
$INTS what catalyst is coming ahead?? Or it's better to dump it??
0 · Reply
peterpancake
peterpancake Oct. 24 at 1:41 PM
$INTS fda approved
1 · Reply
Latest News on INTS
Intensity Therapeutics, Inc. Announces Pricing of Public Offering

Jun 11, 2025, 11:46 PM EDT - 4 months ago

Intensity Therapeutics, Inc. Announces Pricing of Public Offering


Wolfsschanze
Wolfsschanze Oct. 25 at 2:23 PM
$INTS ***Klinische Studien und Daten: Klinische Studien sind entscheidend, um zu zeigen, dass ihre Therapien tatsächlich wirksam sind und weniger Nebenwirkungen haben als traditionelle Chemotherapien oder andere Immuntherapien. Erfolgreiche Ergebnisse aus den laufenden Phase-1- und Phase-2-Studien könnten die Marktposition des Unternehmens erheblich stärken. Partnerschaften und Finanzierungen: Partnerschaften mit größeren Pharmaunternehmen oder zusätzliche Finanzierungsrunden sind wichtig, um die klinischen Tests weiterzuführen. Falls das Unternehmen in der Lage ist, Kooperationen einzugehen oder neues Kapital zu beschaffen, kann dies seine Chancen auf Erfolg weiter steigern.
0 · Reply
Pettechfl
Pettechfl Oct. 25 at 6:54 AM
$INTS https://www.zacks.com/stock/research/INTS/price-target-stock-forecast https://allianceg.com/researchteammember/james-molloy/ https://www.benchmarkcompany.com/leaders/robert-wasserman/ https://www.linkedin.com/in/kumarraja
0 · Reply
peterpancake
peterpancake Oct. 24 at 10:29 PM
$INTS Based on the cash raised through July 2025, we now project to have sufficient cash to fund our current operating plan into the second half of 2026."
0 · Reply
peterpancake
peterpancake Oct. 24 at 8:00 PM
$INTS yeah but there is no news. They literally have said nothing since September 9th. Almost 2 months with nothing other than RS stuff. This is bull crap
0 · Reply
lamMBD
lamMBD Oct. 24 at 7:34 PM
$INTS Part 3 In saying all of that, shares are NOW IN EXTREMELY TIGHT HANDS!!! Catalysts will ignite the spark here and this level will be a thing of the past!! The woulda coulda shoulda conversation!! I have been an investor for over forty plus years.Proud to still be in the game! However, in the 80s and 90s, it wasn't a game. People were more honest looking to help one another out sticking together and beating the markets and it's evil corruption, fighting together so that we all could prosper! Oh how i truly miss those days!! Part 4
3 · Reply
lamMBD
lamMBD Oct. 24 at 7:19 PM
$INTS PART 1 This post is for all longs this is my second time lost first LONG message unfortunately!! After extensive dd, over the last forty eight hours, I have come to the conclusion that the float here in INTS is the tightest that it has ever been!! The numbers that I came up with are 10-15M! If you are paying close attention to how INTS you is trading, it moves very quickly on up buys! What we are waiting for now longs are catalysts to start flowing! When these catalysts start coming out, and they will VERY SOON, there will be no stopping INTS as it heads its way to nasdaq compliance and above!! Part 2 coming up
1 · Reply
peterpancake
peterpancake Oct. 24 at 6:11 PM
CT-based biotech moves ahead with reverse-split plan $INTS https://hartfordbusiness.com/article/ct-based-biotech-moves-ahead-with-reverse-split-plan/
0 · Reply
peterpancake
peterpancake Oct. 24 at 6:09 PM
Connecticut Biotech Firm Intensity Therapeutics Navigates Critical Reverse Stock Split for Long Term Strategy $INTS https://markets.financialcontent.com/wral/article/marketminute-2025-10-24-connecticut-biotech-firm-intensity-therapeutics-navigates-critical-reverse-stock-split
0 · Reply
Viks25
Viks25 Oct. 24 at 1:52 PM
$INTS what catalyst is coming ahead?? Or it's better to dump it??
0 · Reply
peterpancake
peterpancake Oct. 24 at 1:41 PM
$INTS fda approved
1 · Reply
Ultrarich
Ultrarich Oct. 24 at 12:55 PM
$INTS Some birds are taking news, but this company needs more money so dilution will come after RS.
0 · Reply
lamMBD
lamMBD Oct. 24 at 12:06 PM
$INTS INTS has until Dec 2, 2025 to meet the FIRST NASDAQ COMPLIANCE!! If for some reason they have not, they are ELIGIBLE to file for another 180 day extension, taking the Nasdaq Compliancy dealine date out to first or second week in May of 2026!! Also to NOTE!! INTS CASH RUNWAY GOES UNTIL 2ND HALF OF 2026!!! MBD
0 · Reply
lamMBD
lamMBD Oct. 24 at 10:12 AM
$INTS PAUSE lifted and trial resumed News dropping today or Monday morning. JMO! Have a wonderful blessed day and weekend all longs. MBD
0 · Reply
Pettechfl
Pettechfl Oct. 24 at 8:56 AM
$INTS https://www.citybiz.co/article/731787/qa-with-lew-bender-president-ceo-at-intensity-therapeutics/ Recent interview with CEO. It should be criminal that this stock is so low considering the value and upside. I’m dropping all my spare cash into this and feel lucky to have stumbled upon it. Proactive management, giving lectures on the process and keep their eye on the goals. Sucks that their funding has been limited but not for long once new data comes out!
1 · Reply
Pettechfl
Pettechfl Oct. 24 at 8:50 AM
$INTS more quotes: In our phase 1/2 study, we treated over 20 different types of cancer in patients with no options left to them. We saw favorable results in many of those cancers. However, one has to choose a development pathway for marketing approval. Given a lack of resources, we have targeted advanced soft tissue sarcoma, as well as presurgical triple-negative breast cancer, for our first indications. These cancers have a high unmet medical need for improved treatments. We hope that this delivery technology will be a valuable tool across many other cancers in the future.
0 · Reply
Pettechfl
Pettechfl Oct. 24 at 8:49 AM
$INTS qutoes“Treatments such as chemotherapy and immunotherapy impact a patient’s entire body, with toxic side effects. Intensity’s technology takes a different approach, with our drug being injected directly into the patients’ tumors; healthy cells throughout the body are spared. As the cancer cells die, the immune system begins to recognize the cancer. Essentially, we debulk the live cancer and convert a person’s tumor into their own personal anticancer vaccine, inducing a systemic adaptive immune response. Our proprietary chemistry enables the active agents to be soluble in both fat and water simultaneously. Almost all drugs are given intravenously or orally to fight metastatic disease systemically. Our local therapy kills tumors and stimulates the immune system to attack the tumors that we do not inject. After intratumoral injection with INT230-6, the cytotoxic agents disperse throughout the tumor and diffuse into the cancer cells.
0 · Reply
Pettechfl
Pettechfl Oct. 24 at 8:45 AM
$INTS once this company gets one thing through FDA it is going to be a windfall. There are so many cancers that this is going to become first line/first stage treatment for. By this time next year minimum 1-3$ per share. next 5-10 years could be one of the largest oncology companies out there. Gotta hand it to the Founder/CEO, smart guy. He (and I) for that matter could care less about a R/S or stock price near term so long as they get through this first trial and into real money. It’s obvious to me that he knows what they have and know that it is going to be successful. FDA knows too or they wouldn’t have given designation to them. Scalp all you want but I’m all in next few years on this one. Easy 50-100$+ a share years from now after they get multiple cancers on the label with dozens of different chemo/immuno combos. Just need to get the triple negative over the FDA finish line which is just a short matter of time. https://www.citybiz.co/article/731787/qa-with-lew-bender-president-ceo-at-intensity-therapeutics/
0 · Reply
Viks25
Viks25 Oct. 24 at 2:54 AM
$INTS rs coming
0 · Reply
DagZahav
DagZahav Oct. 24 at 12:03 AM
$INTS What is going on with the Nasdaq listing requirement?
0 · Reply
peterpancake
peterpancake Oct. 23 at 9:31 PM
$INTS Now Recruiting Phase 3 Study: INVINCIBLE-3 A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of Intratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared with US Standard of Care in Adult Participants with Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas (NCT06263231)
1 · Reply
SBEEE
SBEEE Oct. 23 at 9:21 PM
1 · Reply
peterpancake
peterpancake Oct. 23 at 9:20 PM
Clinical Research - Intensity Therapeutics $INTS https://intensitytherapeutics.com/clinical-research/
0 · Reply